undamentalytics Newsletter
Sign in

Thermo Fisher Scientific revenue

Thermo Fisher Scientific's revenue was $44.56bn in fiscal 2025, up 3.9% on the year before. Since fiscal 2009 ($9.91bn) it has grown at a compound 9.8% a year. Over the last twelve months it was $47.35bn.

Revenue history

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue9.910.411.612.513.116.917.018.320.924.425.532.239.244.942.942.944.647.4
Growth on the year before—+4.9%+11.2%+8.2%+4.6%+29.0%+0.4%+7.7%+14.5%+16.4%+4.9%+26.1%+21.7%+14.5%−4.6%+0.1%+3.9%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Laboratory Products and Biopharma Services $23.8B 53.5% ▲ 3.5%
Life Sciences Solutions $8.8B 19.7% ▲ 7.6%
Analytical Instruments $7.4B 16.5% ▲ 1.2%
Specialty Diagnostics $4.6B 10.3% ▲ 3.5%
Products and services
Line of business Revenue Share YoY
Products $26B 58.2% ▲ 3.7%
Services $18.6B 71.6% ▲ 4.2%
Instruments $7.3B 28.1% ▼ 1.9%
Consumables $18.7B 41.8% ▲ 6.1%
Geography
Region Revenue YoY
North America $23B ▲ 2.4%
Outside the US $22.3B ▲ 5.6%
United States $22.2B ▲ 2.2%
Europe $11.8B ▲ 8.9%
Asia Pacific $8.1B ▲ 1.8%
Other Regions $1.6B ▲ 2.3%

These categories overlap or exclude eliminations, so shares aren't shown.

From Thermo Fisher Scientific's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Life Sciences Tools & Services: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Thermo Fisher Scientific $47.35bn 8.3% 2.9%
Danaher Corporation $25.61bn 5.5% 1.3%
IQVIA $17.31bn 8.8% 5.2%
Icon PLC $8.25bn 0.8% 83.5%
Agilent Technologies $7.37bn 8.6% 1.8%
Avantor, Inc. $6.64bn 0.9% -1.9%

Compare with peers

Head to head: DHR vs TMOIQV vs TMOICLR vs TMO

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Thermo Fisher Scientific's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Thermo Fisher Scientific.